DISEASE EDUCATION:
Underlined terms can be clicked for more information.
There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). SCLC makes up about 15% of lung cancer cases.
SCLC is a fast-growing cancer that develops when a specific type of lung cell, called a neuroendocrine cell, grows out of control.
Patients with SCLC are often diagnosed after the cancer has reached an advanced stage because symptoms don't typically appear early in the disease.
Small-cell lung cancer makes up about 15% of lung cancer cases The stage of the cancer, or how far it has spread, will determine whether you have limited-stage or extensive-stage disease. The stage of the cancer will also affect your treatment options. Most patients have extensive-stage disease at the time of diagnosis.
Limited-stage cancer is often treated with surgery, radiation, and/or chemotherapy, while extensive-stage SCLC requires chemotherapy and sometimes immunotherapy. Extensive-stage SCLC has a high rate of returning after the first treatment.
Clinical trials may be an option for patients with SCLC.
If you are a physician or another healthcare professional interested in learning more about a tarlatamab clinical trial or referring a patient, please contact an Amgen Medical Information Healthcare Professional.
Where can I get more information?
To determine if you may be eligible for a clinical trial for tarlatamab, talk to your doctor or contact an Amgen Medical Information Healthcare Professional.
